- Global Pharma News & Resources

DPP-IV Inhibitors Markets 2016-2024 - Global Strategic Business Report 2018 -

The "DPP-IV Inhibitors - Global Strategic Business Report" report has been added to's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million.

The Global market is analyzed by the following Drugs:

  • Sitagliptin
  • Vildagliptin
  • Saxagliptin
  • Others

The US market is further analysed in terms of sales by the following drug Segments:

  • Sitagliptin
  • Saxagliptin
  • Linagliptin
  • Alogliptin

The report profiles 14 companies including many key and niche players such as:

  • AstraZeneca Plc. (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly and Company (USA)
  • Merck & Co, Inc. (USA)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Novartis AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)

Key Topics Covered:

1. Introduction, Methodology & Product Definitions

2. Industry Overview

3. The Diabetes Epidemic

4. An Overview Of Drug Classes In Anti-Diabetic Drugs Category

5. A Review Of Select Approved DPP-IV Inhibitor Drugs

6. DPP-IV Inhibitors - An Overview Of The Drug Class

7. Competitive Landscape

8. Global Market Perspective

9. Regional Market Perspective

10. Company Profiles

Total Companies Profiled: 14 The United States (2)

  • Japan (6)
  • Europe (3)
    • Germany (1)
    • The United Kingdom (1)
    • Rest of Europe (1)
  • Asia-Pacific (Excluding Japan) (3)

For more information about this report visit

View source version on

Editor Details

Last Updated: 19-Oct-2018